(NASDAQ: GOSS) Gossamer Bio's forecast annual revenue growth rate of 29.97% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.32%, and while it is forecast to beat the US market's average forecast revenue growth rate of 13.93%.
Gossamer Bio's revenue in 2026 is $55,537,000.On average, 9 Wall Street analysts forecast GOSS's revenue for 2026 to be $7,268,778,519, with the lowest GOSS revenue forecast at $0, and the highest GOSS revenue forecast at $11,483,689,029. On average, 9 Wall Street analysts forecast GOSS's revenue for 2027 to be $14,957,428,684, with the lowest GOSS revenue forecast at $4,554,046,637, and the highest GOSS revenue forecast at $29,325,300,311.
In 2028, GOSS is forecast to generate $29,963,674,195 in revenue, with the lowest revenue forecast at $5,015,459,525 and the highest revenue forecast at $87,292,934,755.